DHODH-IN-33

• Description:

  DHODH-IN-33 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with potent activity against A549 (IC50 = 5.22 μM) and 5637 (IC50 = 3.03 μM) . DHODH-IN-33 induces autophagy-dependent ferroptosis (mitochondrial dysfunction, lipid peroxidation, and ROS accumulation) with no notable toxicity in vivo. DHODH-IN-33 exerts anti-cancer effect by promoting the autophagy-dependent degradation of DHODH. DHODH-IN-33 can be used for non-small cell lung cancer and bladder cancer[1].

• UNSPSC:

  12352005

• Target:

  Autophagy; Ferroptosis; ROS Kinase

• Related Pathways:

  Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  COC1=CC2=C (N (C3C4=CC=CC=C4OC3C2) S (=O) (C5=CC=C (C=C5) C) =O) C=C1

• Molecular Formula:

  C23H21NO4S

• Molecular Weight:

  407.48

• References & Citations:

  [1]Liu CY, et al. Tetrahydrobenzofuro[3,2-b]quinoline: A dual-acting autophagy-dependent DHODH inhibitor that provokes ferroptosis in lung cancer cells. Bioorg Chem. 2025 Dec;167:109203.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  3026839-88-0